Altheus Therapeutics
CompanyUnited States
Altheus Therapeutics develops one asset, in phase 1 (ALTH12-1:4 in ulcerative colitis). Mostly small molecule acting on Oxidative stress and ROS signalling and inflammation; based in the United States.
- Assets
- 1
- Furthest
- Phase 1
- Trials
- 1
- Signals
- 0
Pipeline
1Antioxidant and anti-inflammatory formulation for ulcerative colitis
Phase 1Small moleculeOxidative stress and ROS signallingInflammationulcerative colitis
Full company profiles: pipeline, trials, funding and people.
See Pro- Evidence behind the mechanisms3
- Trials1
- Similar companies6
Updated 7 Oct 2026 · 4 sources